retatrutide trial results Shows 28% Weight Loss in 80 Weeks Retatrutide Helped Adults With Obesity

Description

Phase 2 trial data (NEJM, 2023) showed promising weight reduction results, but long-term safety and cardiovascular outcomes remain under investigation in ongoing Phase 3 trials

Participants in the GLP-1 RA cohort had a greater weight and a more preserved renal function at baseline

doi: 10.1111/dom.13420

This reaction is severe and potentially life-threatening, including symptoms like unease, tingling, dizziness, itching, hives, swelling, difficulty breathing, and fainting.81,107,109 Tanzeum was discontinued by GlaxoSmithKline (GSK) in 2017, primarily due to economic factors.110,111 Despite GSKs attempts to gain a competitive edge through low pricing, Tanzeum failed to achieve sufficient market acceptance.106 In 2017, Tanzeum was removed from the preferred drug list of leading pharmacy benefit manager (PBM) company Express Scripts and was replaced by Eli Lillys Trulicity, highlighting Tanzeums weak market presence.106,108 Moreover, this decision was part of a broad strategic reform led by GSKs new CEO Emma Walmsley.106 This reform aimed to refocus the companys efforts on areas with higher revenue potential, such as respiratory and HIV treatments, as well as oncology and immunology.108 Additionally, Tanzeum struggled to establish a significant market share in the competitive GLP-1RA market, which was another reason GSK decided to withdraw the drug globally.108 Dulaglutide Dulaglutide was approved by the FDA in 2014 for the treatment of T2DM.112 Dulaglutide is a once-weekly long-acting GLP-1RA